Fig. 9.

Neutrophil functions were not affected by MRS2211, a reversible P2Y₁₃ antagonist. (A) Human platelets were pretreated at 37°C with MRS2211 (10, 25, and 50 μM) for 2 minutes and then stimulated with 2MeSADP (100 nM). All tracings are representative of at least three experiments from different donors. (B) CD16 surface expression was determined through flow cytometry in the absence or presence of MRS2211 at concentrations of 25 and 50 μM (n = 4, mean ± S.E.M.) following stimulation with fMLP (10 μM). (C) Neutrophil transmigration was evaluated in the absence or presence of the P2Y₁₃ antagonist at different concentrations (n = 4, mean ± S.E.M.) after fMLP-induced (10 μM) activation. (D) Platelet-neutrophil aggregate formation in response to fMLP (10 μM) was evaluated in the presence of MRS2211 (25 and 50 μM) (n = 4, mean ± S.E.M.; *P ≤ 0.05, PRAS compared with negative control).